In a research report released this morning, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a price target of $147, after hosting a call with a pediatric epilepsy specialist familiar with CBD and artisanal CBD/marijuana formulations to discuss the current treatment paradigm and GW Pharma’s recent Phase 3 results in Dravet Syndrome (DS).

Schimmer wrote, “Based on the data available in the press release of 39% median seizure reduction in Epidiolex treated pts vs. 13% for pbo, the specialist believes this is a robust exciting result and one that is largely in line and confirms the data from the expanded access / artisanal preparations. Though he is very familiar with all the feedback and successful anecdotal results from patients / families, his belief is the Phase 3 results actually replicate the prior open label experience when one closely analyzes the seizure journals kept by patients’ families in the expanded access program.”

“Overall, in his view there remains a broad and high unmet need in both DS and Lennox Gastaut Syndrome (LGS) as well as the broader refractory epilepsy population. Based on the totality of the results so far, the specialist believes the data will ultimately support use of Epidiolex as a broad activity anti-seizure drug with a well-tolerated profile, supporting substantial use potentially on par with Onfi,” the analyst concluded.

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joshua Schimmer has a total average return of -23.6% and a 17.5% success rate. Schimmer has a -6.0% average return when recommending GWPH, and is ranked #3745 out of 3819 analysts.

As of this writing, all the 6 analysts polled by TipRanks rate GW Pharmaceuticals stock a Buy. With a return potential of 107%, the stock’s consensus target price stands at $149.33.